Organization

CSPC Pharmaceutical Group Co., Ltd.

1 abstract

Abstract

Clinical update related to the first-in-human trial of SYS6002 (CRB-701), a next-generation nectin-4 targeting antibody drug conjugate.

Org: Hebei University Affiliated Hospital, Affiliated Cancer Hospital of Harbin Medical University, Jiamusi Cancer and Tuberculosis Hospital, Phase I Clinical Trials Center, CSPC Pharmaceutical Group Limited,